bottom line beat guidanc rais driven
 way compani
indic real surpris expect total
strong soliri mg launch progress drug
enrol onesourc new pts/wk
lower d/c rate real-world trial
work optim row launch file nmo
ultomiri busi start
pnh pdufa ahu data start
mg bridg studi continu
evalu less frequent dose
platform dont expect trial patient
headwind tailwind mani
strensiq weak season
partnership expand presenc
complement space rnai platform pipelin
continu advanc previous indic
go featur multipl move part
soliri launch mg addit nmo label
convers soliri pnh/ahu new
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
price paradigm one dose fit vs
soliri low dose pnh high dose everyth
model/valu adjust pt move
lower bolu estim patient shift
trial commerci lower outer year
price reflect eventu regn/oth competit
roll dcf
remov sbc adjust focu
account nuanc grow
click report updat chart perform
metric
track rel beat/miss
commentari around product serial around quarter includ
impact
enrollment-eu
apac impact
vs
adjust
benefit
impact
trial
contribut
ahu pnh
impact
million
tender order
juli mg
juli
juli
impact order
time relat juli
holiday
impact
due order time
growth us
continu growth
time order
revenu
benefit
work payor
align valu
continu growth
new patient
 germani
agreement uk
franc israel
new fund
ex-u market
previous
test
impact
expir
batch product
serial guidanc updat
non-gaap
non-gaap sg
margin total
start later
year
earli mg launch
addit commentari key programs/pipelin
focus risk profil
nmo data ye
nmo data ye
mg approv
patient
current drug
strong launch soliri
mg track becom
best soliri launch
patient drug march
mg launch track
patient treat jun
onesourc
applic earli
launch first year
patient treat sept
enrol
present primari
endpoint met trend
toward superior
present primari
trend superior
submiss pnh mid
pnh eu
track file japan
on-going studi
children/adolesc
pnh children ahu
on-going studi
children/adolesc
pnh children ahu
ahu adult complet
 start singl pk
data earli file
data earli file
 bridg studi initi
initi late
initi late
initi late
file cta eu
initi studi
initi
file late
initi mg studi
increas trial size
power
superior plan file
trial power
superior file
data initi waiha
anoth pivot studi
complement pharma
dicerna
initi sad pk trial
technolog year
deriv valuat base dcf use discount rate appli
commerci stage biotech compani termin growth rate reflect optimist outlook durabl
compani franchis includ million product revenu reflect potenti busi
risk price target includ intensifi competit threat formid biopharma compani along potenti
amplifi price pressur failur build compel develop pipelin
articl articl
time dissemin octob
analyst josh schimmer shenston huang ami liu maneka mirchandaney primarili respons prepar research
report attest follow view opinion render research report reflect person view subject
compani issuer part research analyst compens directli relat specif
recommend view research report
